Taiyo Pacific Partners L.P. Logo
Oct
18th

AsiaHedge

Where others have failed, Taiyo made its mark in the Japanese alternatives space through friendly activism and a deep understanding of the culture.

Download full article

Aug
6th

Brian K. Heywood, Chief Executive Officer and Managing Partner of Taiyo Pacific Partners, said, "Japanese pharmaceutical makers have grown sales by 4% annually over the past 10 years, with many more growth opportunities given Japan's aging society. Drug makers themselves, however, face large regulatory risks and heavy burdens from R&D expenses surging 10% per year over the same period. Pharmaceutical companies in Japan face a strong need to outsource this R&D, and the trend is just beginning with only 15% of Japanese drug R&D outsourced vs. 50% in the US. As a leading outsourced research provider in Japan, CMIC is positioned to enjoy the strong growth in pharmaceutical R&D without facing approval risks. We have been impressed by CMIC management's commitment to shareholders and are confident they will continue to create shareholder value."